Shakya Neeraj, Vedi Satish, Liang Chao, Yang Fang, Agrawal Babita, Kumar Rakesh
Department of Laboratory Medicine and Pathology, 7-28 Heritage Medical Research Centre, University of Alberta, Edmonton, AB T6G 2S2, Canada.
Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
Bioorg Med Chem Lett. 2014 Mar 1;24(5):1407-9. doi: 10.1016/j.bmcl.2014.01.024. Epub 2014 Jan 17.
Hepatitis C virus (HCV) infection is one of the major health problems worldwide. If left untreated, it leads to liver cirrhosis, liver cancer and death. Herein, we report synthesis and anti-HCV activity of a new class of pyrimidine nucleosides possessing a 4'-carboxymethyl (9-16, 21 and 23) or 4'-carboxamide function (17-19 and 24). Among these, 10-12 (EC50=33.1-42.4 μM), 14 and 21 (EC50=43.4-59.5 μM) exhibited potent activity in HCV-1a replicon cells without any toxicity to parent Huh-7 cells (CC50=>829-1055 μM). The anti-HCV activities demonstrated by this unusual class of compounds were superior to that of ribavirin (EC50=81.9 μM). Further, the most active analog, 12, was found to interact synergistically with ribavirin to inhibit HCV RNA replication.
丙型肝炎病毒(HCV)感染是全球主要的健康问题之一。如果不进行治疗,它会导致肝硬化、肝癌甚至死亡。在此,我们报告了一类新型嘧啶核苷的合成及其抗HCV活性,这类核苷具有4'-羧甲基(9 - 16、21和23)或4'-羧酰胺官能团(17 - 19和24)。其中,10 - 12(EC50 = 33.1 - 42.4 μM)、14和21(EC50 = 43.4 - 59.5 μM)在HCV - 1a复制子细胞中表现出强效活性,且对亲本Huh - 7细胞无任何毒性(CC50 > 829 - 1055 μM)。这类不同寻常的化合物所表现出的抗HCV活性优于利巴韦林(EC50 = 81.9 μM)。此外,发现活性最高的类似物12与利巴韦林协同作用以抑制HCV RNA复制。